PPARA and metabolic dysfunction-associated steatotic liver disease: Saroglitazar, the first approved dual-PPAR α/γ agonist (only in India), has also been trialed as a potential drug for NAFLD because of its beneficial effect on fatty liver in diabetic patients with NAFLD [132].